Satellos Bioscience Inc. (MSCLF) Form 6-K — Jul 8, 2026
Satellos Bioscience announced positive six-month interim data from its Phase 2 TRAILHEAD study evaluating SAT-3247 in adults with Duchenne muscular dystrophy. The results demonstrated a consistent picture of stability or improvement across multiple clinically relevant measures, including muscle composition, total effort, and biomarkers of muscle damage. All four participants in the study showed a mean improvement of 3.7% in muscle fat fraction as measured by MRI and a 34% increase in total effort. Additionally, the mean creatine kinase level, a biomarker of muscle damage, declined 38% from baseline, and the safety profile remained favorable with no serious treatment-emergent adverse events.
Key figures
- Participants
- 4
- Mean CKDecline
- 38%
- Compliance Rate
- 100%
- Mean Drug Exposure Days
- 186
- Mean Peds QLImprovement
- 6.94 points
- Mean Total Effort Improvement
- ~34%
- Mean Muscle Fat Fraction Improvement
- -3.7%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.